Does Barrett’s Esophagus Length Still Matter? Contemporary Implications for Risk Stratification, Surveillance, and Endoscopic Therapy

Longer Barrett esophagus (BE) segments are associated with worse outcomes than shorter segments. However, it remains uncertain whether BE length is still a clinically actionable variable in modern surveillance, risk stratification, and treatment pathways. We reviewed current literature on the relevance of BE length as a predictor of gastroesophageal reflux disease (GERD) severity, cancer risk, treatment outcomes, regression after treatment, and remission after ablation. BE length correlates with hiatal hernia size, esophageal dysmotility, esophagitis, and acid exposure time. Long-segment BE carries a greater risk of dysplasia or progression to esophageal adenocarcinoma than short-segment BE, although smaller segments are not risk-free. Longer BE length was associated with treatment failure and increased post-treatment pain. BE length also predicted recurrence of BE, dysplasia, or adenocarcinoma after endoscopic ablation therapy. In conclusion, most current studies report BE outcomes without stratifying results by length. BE length, however, functions as a continuous clinical variable that influences multiple aspects of care, including progression risk, surveillance intervals, treatment complexity, likelihood of eradication, recurrence after therapy, and incorporation into emerging prediction models. In other words, the contemporary importance of length lies less in preserving a historical cutoff than in recognizing length as one component of multidimensional risk stratification.